Looking beyond established patterns in prostate cancer with COSMIC v105

Date: 18 November 2026 | 5 minute read

Looking beyond established patterns in prostate cancer with COSMIC v105

Behind every prostate cancer diagnosis is an individual disease, shaped by a unique combination of biological and genomic factors. With over 1.5 million men diagnosed in 2024, improving our understanding of these differences is an important part of the wider effort to improve outcomes for people affected by prostate cancer.

Genomic research has already revealed recurrent alterations that help define some of the more established molecular patterns of prostate cancer. However, the disease is remarkably diverse, with genomic characteristics varying between individuals and even within individual tumours. Looking beyond commonly studied patterns can therefore reveal valuable insights into prostate cancer, from rare tumour alterations to genomic differences in previously underrepresented populations.

With this in mind, prostate cancer is our key focus for COSMIC v105 as we work towards more comprehensive coverage of the disease across the COSMIC Knowledgebase. By capturing and curating findings from across the literature, including less well-represented areas of prostate cancer genomics, we aim to provide researchers with a more complete foundation for studying the disease. Ultimately, we aim to deepen our understanding of the biological differences that shape prostate cancer.

In this blog, we explore three studies curated for v105 that illustrate why this breadth matters. Moving from established molecular patterns, to a rare histological subtype, and finally to findings from a historically underrepresented population, they show how looking more widely can reveal parts of prostate cancer biology that might otherwise be missed.

A photo of an academic paper on a desk, the text is illegible. A pair of hands are visible, this person is highlighting the paper with pink highlighter

Finding meaning in established genomic patterns

Some of the clearest insights into prostate cancer diversity come from recurrent genomic alterations already recognised across the disease.

One study curated for v105 examined men with de novo metastatic castration-sensitive prostate cancer, exploring whether mutations in SPOP were associated with differences in outcomes. Among patients with additional genomic and clinical data, SPOP-mutated tumours were associated with substantially longer progression-free and overall survival than SPOP wild-type tumours.

Findings like these demonstrate why characterising recurrent alterations matters. Identifying a mutation is only part of the picture; understanding how it relates to a tumour's broader biology and behaviour can reveal meaningful differences between prostate cancers that might otherwise appear similar.

However established molecular patterns are only one part of prostate cancer’s genomic diversity. Examining rarer forms of the disease can reveal a very different picture.

What rare prostate cancers can reveal 

Some of the most revealing findings emerge when researchers look beyond the more familiar forms of prostate cancer. One study curated for v105 examined PIN-like ductal carcinoma, a rare subtype with a distinct molecular profile.

Among just five cases, three carried activating alterations affecting the RAS/RAF pathway, including BRAF p.K601E. Alterations in this pathway are exceptionally rare in conventional primary prostate cancer, making their accumulation within this small group particularly striking.

The study highlights how examining rare subtypes in detail can bring unusual genomic patterns into sharper focus. Capturing these findings alongside data from more common forms of the disease helps build a broader picture of the biological diversity underlying prostate cancer, ultimately aiming to find treatments for all patients.

Ensuring a more representative view of prostate cancer

Understanding the diversity of prostate cancer also means considering whose disease is represented in genomic research. African and African-American men are disproportionately affected by prostate cancer, yet these populations have been underrepresented in sequencing studies.

A study curated for v105 examined prostate cancers from African-American men and identified recurrent loss-of-function mutations in ERF in around 5% of cases. These alterations had not previously been observed in prostate cancer, revealing a genomic feature that might have remained overlooked without studying a more diverse population.

Research across men of several African ancestries has also identified differences from European prostate cancer cohorts, including a higher mutational burden and differences in recognised driver alterations.

Together, these findings reinforce the importance of broader representation in genomic research. Building a more complete picture of prostate cancer biology depends not only on studying more tumours, but on capturing the diversity of the people affected by the disease.

Building a fuller picture for the future of prostate cancer research

These studies show that understanding prostate cancer means looking beyond the patterns we already know. Established alterations can reveal meaningful differences between tumours, while rare subtypes and more representative study populations can expose biology that might otherwise remain hidden.

For the people affected by prostate cancer, that diversity is part of the reality of the disease. Building a fuller understanding therefore depends on research that reflects its complexity and the breadth of people it affects.

With prostate cancer as a key focus for COSMIC v105, we have expanded our expert-curated coverage of this diverse disease. By bringing findings from across the research landscape together in the COSMIC Knowledgebase, v105 provides researchers with a broader foundation for exploring prostate cancer biology and the differences that shape it.